Research article Special Issues

Electrospinning of chitosan from different acid solutions

  • Electrospinning is a production technique for obtaining polymer nanofibers relatively low-cost and straightforward to produce fine fibers. Chitosan (CTS) is a well-known biopolymer widely used for drug delivery, hydrogels, tissue engineering, wound healing, and mats. This work aims to study different chitosan-organic acid solutions' conductivity using electrochemical impedance spectroscopy and equivalent circuit fitting to understand this parameter's influence in the electrospinning process for fiber formation in different organic acids as solvents. The conductivity of dilute chitosan solutions decreases until reaching a minimum value as chitosan concentration increases; conductivity increases linearly as concentration increases. We measured solution resistance, polarization resistance, and relaxation time of chitosan solutions in acetic, formic, lactic, and citric acids using electrical impedance spectroscopy with equivalent circuit modeling. There is no direct correlation between the electrospinnability of the different organic acids solutions with their solution conductivity. We obtained chitosan nanofibers and particles when electrospun a chitosan concentrated solution (4 wt%) in concentrated acetic acid (90 vol%) and obtained submicron particles with a more diluted solution (1 wt%) in concentrated acetic acid (90 vol%). We also obtained chitosan particles from formic acid solutions and completely different ordered and elongated particles with citric acid solutions. Getting insight into the organic acid-chitosan interactions will help improve the electrospinning process to obtain fibers, particles, or both in a controlled fashion and may help design tailored materials.

    Citation: Sergio A. Salazar-Brann, Rosalba Patiño-Herrera, Jaime Navarrete-Damián, José F. Louvier-Hernández. Electrospinning of chitosan from different acid solutions[J]. AIMS Bioengineering, 2021, 8(1): 112-129. doi: 10.3934/bioeng.2021011

    Related Papers:

    [1] Fumiaki Uchiumi, Yoko Ogino, Akira Sato, Sei-ichi Tanuma . Insights into the development of effective materials to suppress replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). AIMS Bioengineering, 2020, 7(3): 124-129. doi: 10.3934/bioeng.2020012
    [2] Xiang-Xiang Guan, Xiao-Juan Zhu, Zhao-Hui Deng, Yu-Rong Zeng, Jie-Ru Liu, Jiang-Hua Li . The association between nicotinamide N-methyltransferase gene polymorphisms and primary hypertension in Chinese Han Population. AIMS Bioengineering, 2021, 8(2): 130-139. doi: 10.3934/bioeng.2021012
    [3] Kranthi Kumar Lella, Alphonse PJA . A literature review on COVID-19 disease diagnosis from respiratory sound data. AIMS Bioengineering, 2021, 8(2): 140-153. doi: 10.3934/bioeng.2021013
    [4] Cong Toai Truong, Kim Hieu Huynh, Van Tu Duong, Huy Hung Nguyen, Le An Pham, Tan Tien Nguyen . Model-free volume and pressure cycled control of automatic bag valve mask ventilator. AIMS Bioengineering, 2021, 8(3): 192-207. doi: 10.3934/bioeng.2021017
    [5] Uri Adrian Prync Flato, Karina Vilariço Ferreira, Piero Biteli, Daniela Ortega Balbo Rodrigues Reina, Fábio Tadeu Rodrigues Reina, Fausto Tucunduva Vernaschi, Gabriela Achete de Souza, Gyovanna Sorrentino dos Santos Campanari, Júlia Novaes Matias, Vinícius Marinho Lima, Tereza Lais Menegucci Zutin, Rogério Leone Buchaim, Daniela Vieira Buchaim, Sandra Maria Barbalho . Rabdomyolysis as a serious complication of COVID-19. AIMS Bioengineering, 2021, 8(2): 165-172. doi: 10.3934/bioeng.2021015
    [6] Mariem Jelassi, Kayode Oshinubi, Mustapha Rachdi, Jacques Demongeot . Epidemic dynamics on social interaction networks. AIMS Bioengineering, 2022, 9(4): 348-361. doi: 10.3934/bioeng.2022025
    [7] Kuna Dhananjay Rao, Mudunuru Satya Dev Kumar, Paidi Pavani, Darapureddy Akshitha, Kagitha Nagamaleswara Rao, Hafiz Tayyab Rauf, Mohamed Sharaf . Cardiovascular disease prediction using hyperparameters-tuned LSTM considering COVID-19 with experimental validation. AIMS Bioengineering, 2023, 10(3): 265-282. doi: 10.3934/bioeng.2023017
    [8] Eduardo Federighi Baisi Chagas, Piero Biteli, Bruno Moreira Candeloro, Miguel Angelo Rodrigues, Pedro Henrique Rodrigues . Physical exercise and COVID-19: a summary of the recommendations. AIMS Bioengineering, 2020, 7(4): 236-241. doi: 10.3934/bioeng.2020020
    [9] Mehmet Yavuz, Waled Yavız Ahmed Haydar . A new mathematical modelling and parameter estimation of COVID-19: a case study in Iraq. AIMS Bioengineering, 2022, 9(4): 420-446. doi: 10.3934/bioeng.2022030
    [10] George H McArthur IV, Pooja P Nanjannavar, Emily H Miller, Stephen S Fong . Integrative metabolic engineering. AIMS Bioengineering, 2015, 2(3): 93-103. doi: 10.3934/bioeng.2015.3.93
  • Electrospinning is a production technique for obtaining polymer nanofibers relatively low-cost and straightforward to produce fine fibers. Chitosan (CTS) is a well-known biopolymer widely used for drug delivery, hydrogels, tissue engineering, wound healing, and mats. This work aims to study different chitosan-organic acid solutions' conductivity using electrochemical impedance spectroscopy and equivalent circuit fitting to understand this parameter's influence in the electrospinning process for fiber formation in different organic acids as solvents. The conductivity of dilute chitosan solutions decreases until reaching a minimum value as chitosan concentration increases; conductivity increases linearly as concentration increases. We measured solution resistance, polarization resistance, and relaxation time of chitosan solutions in acetic, formic, lactic, and citric acids using electrical impedance spectroscopy with equivalent circuit modeling. There is no direct correlation between the electrospinnability of the different organic acids solutions with their solution conductivity. We obtained chitosan nanofibers and particles when electrospun a chitosan concentrated solution (4 wt%) in concentrated acetic acid (90 vol%) and obtained submicron particles with a more diluted solution (1 wt%) in concentrated acetic acid (90 vol%). We also obtained chitosan particles from formic acid solutions and completely different ordered and elongated particles with citric acid solutions. Getting insight into the organic acid-chitosan interactions will help improve the electrospinning process to obtain fibers, particles, or both in a controlled fashion and may help design tailored materials.



    At the end of 2019, patients with pneumonia symptoms were admitted to hospitals in the province of Wuhan in China. These patients rapidly evolved into critical respiratory failure and acute respiratory distress syndrome (ARDS). Later enough, Chinese researchers identified the pathological agent linked to this severe pneumonia: a novel coronavirus that would later be named SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2), which causes the coronavirus disease of 2019 (COVID-19) [1][3].

    Coronaviruses are a set of enveloped, single-stranded, positive-sense RNA genome viruses that are capable of infecting humans and promoting respiratory and gastroenterological infections. There are four subfamilies of coronaviruses: alfa, beta, gamma, and delta. The SARS-CoV-2 belongs to the beta family, along with other coronavirus linked to severe diseases related to the respiratory tract [4],[5].

    Although this new coronavirus is responsible for such severe respiratory symptoms, the SARS-CoV-2 infection can be mild or asymptomatic, which could explain how fast COVID-19 spread throughout the world. Since its identification and nomination by the World Health Organization (WHO) in early 2020, this novel virus is confirmed in 216 countries, and the world prevalence reaches about 8 million people infected and almost half a million deaths, according to WHO [6],[7].

    The moderate cases of COVID-19 cause atypical pneumonia with dry cough, fever, and progressive dyspnea. Other upper airway respiratory symptoms can be detected, such as odynophagia, nasal constipation, and sneezes. Gastrointestinal symptoms can also be present such as vomiting and diarrhea, especially in children. The incubation period is 1 to 7 days, and the median incubation period is of 3 days. Moderate to severe clinical features will happen between 7 to 11 days after the infection [8][10].

    Recent research aims to understand the pathophysiology of the SARS-CoV-2 and the onset of COVID-19. It is believed that the infection caused by the virus in alveolar epithelial cells, mediated by the angiotensin-converting enzyme II (ACE2) as a receptor, causes an intense inflammatory response by the immune system that results in a cytokine storm and disseminate inflammation, responsible for tissue lesions not only in the respiratory tract but also in the kidneys, liver and cardiac cells. The radiologic findings (ground-glass patterns, consolidations, and alveolar exudates) and laboratory markers (protein-C-reactive and lactic dehydrogenase) corroborate with the extensive inflammation process [11][13].

    Risk factors to the severe forms of COVID-19 include age (>60 years), obesity, dyslipidemia, diabetes, hypertension, and other cardiovascular diseases, which could be related to a less competent immune response and increased inflammatory patterns to the infection [14][16].

    Nevertheless, it is essential to highlight that COVID-19 is not the only pandemic that is threatening lives in the 21st century. There is a relevant increase in the prevalence of cardiovascular diseases, which are a reflection of the increase in the prevalence of diabetes, dyslipidemia, obesity, and hypertension. In the United States, about 40% of all adults have metabolic syndrome (MS), and it is estimated to affect a quarter of the world population. Alongside that, it is estimated that the world prevalence of diabetes is of 8.8%, and the global prevalence of obesity is of 604 million adults [17][19].

    Furthermore, it is possible to suggest that the presence of metabolic syndrome is a risk factor in developing the critical forms of coronavirus disease. The use of an artificial intelligence framework could predictive analytics capabilities applied to real patient data and could provide fast clinical decision-making support [20]. Therefore, it is imperative to comprehend the relation between MS and the pathophysiology of COVID-19 to manage the disease in these susceptible individuals better. In this light, this work aims to build a descriptive review of the relationship between the factors inherent to MS and COVID-19, in order to better clarify the mechanisms belonging to this association.

    PUBMED-Medline database was consulted to build this descriptive review. The descriptors that were used were COVID-19 or SARS-CoV-2 and metabolic syndrome or diabetes or hypertension or dyslipidemia or cardiovascular diseases. One hundred forty-nine articles were found in the databases that were consulted. After removing duplicates, 56 articles related to COVID-19 and MS parameters were selected. Other related articles were also consulted and helped to prepare the introduction and the discussion section.

    The modern lifestyle creates modifications in dietary habits and physical activity, increasing the incidence of chronic diseases, including MS. This condition is a cluster of clinical findings made up of abdominal obesity, hyperglycemia, high triglyceride levels, low high-density lipoprotein (HDL-c) levels, and hypertension. It is a prothrombotic and pro-inflammatory state characterized by increased inflammatory cytokine activity. In addition to inflammatory dermatoses, such as psoriasis, lichen planus, and hidradenitis suppurativa, MS is also associated with accelerated cardiovascular diseases, hyperuricemia, chronic kidney disease, and obstructive sleep apnea. The therapeutic options are limited to treatments for hypertension, hyperglycemia, and hypertriglyceridemia, as well as dietary control measures and regular exercise practice [21],[22].

    The global prevalence of MS differs depending on geographic and sociodemographic factors, as well as the diagnostic criteria used. National Health and Nutrition Examination Survey (NHANES) data estimate that 35% of adults in the United States, and as much as 50% of the over-60 population, carry a diagnosis of this condition (30.3% in men and 35.6% in women) [21].

    As the prevalence of MS increases, so has research on it. Studies have proposed that adipocytes can play different endocrine functions and are closely related to the pathogenesis of this syndrome. The brown adipocytes that are in lower concentrations in individuals with MS present much more mitochondria in the cytoplasm and are enriched with more uncoupling protein 1 (UCP1) that can induce thermogenesis. When there is an increase in abdominal fat, there is a reduction in brown adipose tissue and an increase in white adipocytes that are related to a pro-inflammatory state. Anti-inflammatory macrophages (M2) are changed by pro-inflammatory macrophages (M1), leading to the release of many adipokines. It is observed an imbalance in the release of leptin, visfatin, and adiponectin and an increase in free fatty acids levels, resulting in insulin resistance [19].

    Other factors are also related to MS, such as genetic/epigenetic factors, the predominance of a sedentary lifestyle, quality and composition of food, and composition of gut microbes. No single remedy can be prescribed for its eradication or even curtailment, but it is a disease that certainly deserves attention because of its high incidence in the world, and nowadays, we should also consider that it as a risk factor for COVID-19 complications [19],[23].

    The 2019 coronavirus disease pandemic (COVID-19) is responsible for a global health threat in the world. COVID-19 is an infectious disease with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and the first case was identified in patients in contact with a seafood market in the city of Wuhan, Hubei Province-China in December 2019. Despite not having a high mortality rate (ranging from 2 to 3% depending on the country), the condition has reached global proportions and was responsible for many deaths, which makes the COVID-19 pandemic a substantial challenge for society and their respective rulers [3],[24].

    The coronavirus presents four subtypes (α, β, γ e δ) and the SARS-CoV-2 is a type of β coronavirus. The SARS-CoV-2 connects with type II pneumocytes by its capacity to bind with angiotensin-converting enzyme 2 (ACE2). The viral infection is cytopathic to human airway epithelial cells and alveolar cells. The distribution of the ACE-2 receptor is broad on the cardiac, renal, intestinal, and endothelial cells, also consisting of the target organs involved and the clinical scenario of COVID19 infection. The pathogenesis of this disease is mostly unknown. However, it may mimic SARS to some extent but is known that the viral infection of pneumocytes induces local inflammatory responses promoting the release of cytokines interleukin-1β (IL-1β), IL-6, transforming growth factor-β1 (TGF-β1), tumor necrosis factor-α (TNF-α) and numerous chemokines that serve to recruit circulating leukocytes. In many forms of COVID-19, the ensuing inflammatory cascade may lead to a cytokine storm, elevating serum cytokine levels, including IL-2, IL-7, IL-10, granulocyte colony-stimulating factor (G-CSF), monocyte chemotactic protein (MCP), and TNF-α. The cytokine storm is believed to be a key factor driving both acute respiratory distress syndrome (ARDS) and extra-pulmonary organ failure, like peripheral lymphopenia. The serum levels of cytokines are significantly increased in patients with ARDS, and the degree of increase is positively correlated with mortality rate [3],[25],[26].

    The peripheral lymphopenia occurs due to the compartmentalization of apparent recruitment of these cells into virus-infected lung tissue rather than any specific virus-mediated suppression. This modulatory capacity is seen by increased activation in HLADR + CD38 + T cells in peripheral blood and an increase in subetaoups os CD4 + T cells [3],[25].

    Higher viral loads were found in the nasal cavity as compared to the throat in symptomatic and asymptomatic subjects. Patients can be infectious for as long as the symptoms last and even on clinical recovery. The infected droplets can spread 2 meters and deposit on surfaces being viable for days in favorable atmospheric conditions. People can get this disease by inhalation of these droplets or touching surfaces and then touching the airways and eyes. Transplacental transmission has not been described [24]. All of these factors imply high transmissibility and a high chance of complications, especially in patients with comorbidities such as MS.

    The increase in visceral or centripetal obesity is an element of great concern due to the possibility of induction of a low-grade pro-inflammatory state, with an abundant environment of inflammatory cytokines and adipokines that corroborate to generate insulin resistance, arterial hypertension, and dyslipidemia. For these reasons, obesity constitutes the central pillar in the genesis of MS. Among the cytokines associated with obesity, the well-known are TNF-α, IL-1, IL-6, PAI-1, leptin, IL-17, IL-23, and TGF-β [27][29].

    The cytokine storm presents both in chronic obesity and in the pathophysiological arsenal of COVID-19 is an environment permeated by an abundance of pro-inflammatory cytokines that favors the modulation of hyperbolic and dysfunctional responses, contributing to increased vascular permeability and tissue invasion by leukocytes. These responses favor cell damage, harm to the occlusive junctions of the respiratory epithelium, and increase the vulnerability to the onset of severe respiratory failure due to a drop in lung function and, consequently, negative outcomes, resulting in substantial impact in COVID-19 prognosis [25],[30],[31].

    Furthermore, it is postulated that the stimulation to the production of IL-17 and IL-23 in obese subjects favor the shift towards a dysfunctional and inefficient immunological response to viral infections, which could contribute to the permanence and morbidity and mortality of COVID-19 in obese patients. It is also postulated that adipose tissue can be used as a reservoir for some viruses so that obesity can favor the worsening and criticality of SARS-CoV-2 infection [28],[32].

    Nevertheless, it is worth noting that the pro-inflammatory secretory pattern intrinsic to obesity, associated with bad dietary habits, contributes to damage to the homeostasis of the intestinal microbiome. Gut dysbiosis, in turn, constitutes an imbalance in the immunity of the gastrointestinal tract (GIT), contributing to the invasion of pathogens through the epithelium by increasing intestinal permeability. Considering factors as the expression of ACE2 in the GIT epithelial tissue, the use of this molecule by SARS-CoV-2 in its virulence and invasion mechanisms, and the negative effects of obesity on the microbiota and the integrity of the intestinal mucosal barrier, this triad may constitute an important element in the link between COVID-19 and obesity [30],[33][35].

    In short, more than 70% of patients with COVID-19 who require intensive care are obese. This fact allows us to infer that the collision between these epidemics of public health constitutes an element of alarm and care. Obesity contributes to increased morbidity and mortality due to COVID-19 in many different ways. However, the pillar that best supports this relationship is based on overlapping inflammatory states, added to damage in immunological homeostasis [28].

    Type 2 diabetes mellitus (T2D) has its pathophysiology strengthened by the sedentary lifestyle associated with excessive intake of sugars, fats, and products rich in preservatives and dyes. Also, as already mentioned, central obesity is a significant stimulus for the development of insulin resistance, contributing to the generation of hyperglycemia and oxidative stress [29],[36],[32].

    T2D has been a reported risk factor in patients with COVID-19, being correlated to a higher need for intensive care, invasive interventions, and poor prognosis, with increase morbidity and mortality. Decompensated T2D has been reported as a significant predictor of other viral infections, including Influenza A (H1N1), SARS-CoV, MERS-CoV, and currently, SARS-CoV-2 [37][39].

    Hyperglycemia stimulates the generation of advanced glycation ends (AGEs), essential elements that generate oxidative stress and damage to the vascular endothelium. Besides, hyperglycemia favors an increased synthesis of adhesion molecules, which effectively contribute to leukocyte diapedesis and tissue damage, favoring the onset of severe respiratory failure due to impaired lung function [40],[41].

    Indeed, studies have shown that diabetic patients tend to reduce forced vital capacity and forced expiratory volume in the first second in pulmonary function tests. Thus, pneumonia caused by SARS-CoV-2 tends to be exacerbated and more critical in these patients. Other studies infer that some viruses use glucose in favor of their viral replication so that hyperglycemia can contribute to increased viral load and severity of COVID-19 in diabetic patients [37],[42].

    It is also important to highlight the association of T2D with a chronic low-grade inflammatory pattern, whose association with the cytokine storm mentioned above, tends to contribute to higher morbidity and the generation of negative outcomes. Moreover, T2D has already been strongly associated with inhibition of the lymphocyte proliferative response and reduction in the mechanisms of innate and humoral immunity, so that this immunodepression is linked to higher vulnerability to the development and worsening of infections, including the threatening COVID-19 [25],[37],[43].

    No less important is the relationship between T2D and homeostasis dysfunction between coagulation mechanisms and fibrinolysis, favoring a prothrombotic state. These factors, added to the action of AGEs on the vascular endothelium, favor morbidity and mortality due to cardiovascular, cerebrovascular, and thromboembolic diseases, through hypercoagulability and endothelial injury [44],[45].

    From this perspective, T2D is shown to be one of the main comorbidities associated with critical and worse prognosis in patients with COVID-19. This potentially lethal association is based on inflammatory, oxidative, and immunosuppressive mechanisms associated with the harmful multisystemic actions of hyperglycemia in the presence of decompensated T2D [37],[46].

    The main manifestations of COVID-19 are respiratory symptoms; however, there are reports of patients who presented severe cardiovascular manifestations, such as hypertension and heart failure. Hypertension affects more than 1 billion people around the world and is characterized by chronic elevation of blood pressure to equal or greater than 140/90 mmHg, contributing to the development of cardiovascular diseases. Patients with hypertension show an increased risk of developing COVID-19, as well as an increased risk of unfavorable outcomes. For these reasons, it is crucial to understand the mechanisms behind this relationship as a way to improve the therapeutic approach of these patients [47][50].

    The receptor for SARS-CoV-2 is the ACE2, a membrane-bound aminopeptidase that participates in the renin-angiotensin system (RAS), crucial to the regulation of blood pressure and electrolyte and water balance. The virus connects to ACE2 through its spike protein S, leading to a series of alterations that culminates in the internalization of the complex. The primary function of ACE2 is the degradation of angiotensin 2 in angiotensin 1–7. Angiotensin 2 promotes the desensitization of baroreceptors, vasoconstriction, sodium retention, oxidative stress, inflammation, and fibrosis, contributing to hypertension and tissue injury. On the other hand, angiotensin 1–7 has protective effects, such as anti-inflammatory and anti-fibrotic actions, apart from enhancing baroreceptor sensitivity [47],[51][54].

    Taking into consideration that patients with cardiovascular diseases have increased secretion of ACE2, it is easy to understand why these people are more susceptible to COVID-19. One of the reasons for the increased expression of ACE2 in these patients may be due to the use of RAS inhibitors as a treatment for hypertension. These drugs upregulate the ACE2, increasing the risks of cell invasion. Despite that, the discontinuation of these medications is not recommended. Moreover, hypertension is more likely to affect older people, also considered a risk group for COVID-19 [16],[47],[55].

    Hypertension was also considered as being a worse prognoses factor for COVID-19. In the study of Wang et al. (2020), among patients with severe symptoms of COVID-19, 58% had hypertension. Also, approximately 35% of patients who progressed to death had a history of hypertension. According to Li et al. (2020), 28.8% of the patients with hypertension needed to be admitted to the intensive care unit [47],[48],[56].

    After the connection of the virus with the ACE2, the complex virus-ACE2 is internalized by the cell, resulting in a decreased availability of this enzyme. As a result, there is an accumulation of angiotensin 2, since ACE2 degrades this molecule. This process leads to exacerbation of lung tissue damage due to two mechanisms: the great invasion of the lung cells by the virus initially and, after depletion of ACE2, due to the action of angiotensin 2 in pulmonary tissue. Angiotensin 2 in the lungs causes vasoconstriction, inflammation, fibrosis, and pulmonary edema, which contributes to the loss of pulmonary function, leading to acute respiratory distress syndrome (ARDS). Also, angiotensin 2 accumulation leads to exacerbation of hypertension, which further complicates the cases. Lastly, angiotensin 2 also acts in the heart, in addition to direct virus injure due to the presence of ACE2, compromising cardiac function. These mechanisms may contribute to the number of severe cases and mortality in patients with hypertension and COVID-19 [16],[47],[53][57].

    Dyslipidemia is characterized by high serum levels of triglycerides (TG) and cholesterol, such as very-low-density lipoprotein (VLDL) and low-density lipoprotein (LDL), as well as low serum levels of high-density lipoprotein (HDL). This condition contributes significantly to the development of atherosclerotic cardiovascular disease due to chronic vascular exposure to oxidative stress and inflammation [47],[58][60].

    Studies have found that cholesterol can facilitate the interaction of the virus with ACE2, favoring the infection. Also, fat tissue is postulated to serve as a reservoir for the virus in COVID-19. In terms of complications, hyperlipidemia is associated with vascular dysfunction and increased risks of atherothrombotic events. The virus can also cause direct endothelial damage, and the cholesterol may serve as a replication site for the SARS-CoV-2 in the endothelium, increasing the risks for acute thrombotic events. As a result, the presence of obesity-associated to dyslipidemia was associated with an increased risk of infection by the virus, as well as the development of complications and severity of the disease [58],[61],[62].

    Wei et al. (2020) found decreased levels of LDL, HDL, and total cholesterol in patients with COVID-19, proportional to the severity of the disease. HDL and triglycerides levels were also decreased mainly in critical cases. On the other hand, levels of C-reactive protein (CRP) and IL-6 were significantly increased in those patients. One reason for these alterations in COVID-19 patients may be due to liver damage, which reduces LDL biosynthesis. Another reason is the inflammation itself, which alters the lipid metabolism, mainly by IL-6, which decreases cholesterol transport in the liver. Lastly, it is postulated that the SARS-CoV-2 can alter the permeability of the endothelium, leading to a leak of cholesterol to the interstice, which, in alveolar space, can contribute to exudate formation, found in the lungs of COVID-19 patients [58],[63].

    In a long-term analysis performed in patients with a history of SARS-CoV infection, it was found that lipid metabolism was dysregulated. Approximately 68% of the patients had hyperlipidemia, 44% cardiovascular system abnormalities, and 60% had disorders of glucose metabolism. Compared to individuals with no history of the infection, these patients presented higher concentrations of free fatty acids (FFA), lysophosphatidylcholine, lysophosphatidylethanolamine, and phosphatidylglycerol. In fact, there is a relationship between viral infection and increased risk for atherosclerosis due to the increased production of lipoprotein and fibrinogen, predisposing the patient to atherothrombotic events. The same effects can be expected for COVID-19 in the long term, due to the resemblance of SARS-CoV-2 and SARS-CoV [47],[64].

    In conclusion, it is already well established in the literature that comorbidities such as hypertension, diabetes, obesity, and dyslipidemia isolated are related to several diseases and, COVID-19 was recently included. Each comorbidity contributes in its way to increase the risk or agammaavate the disease, although they often appear combined, such as in the MS in which the risk becomes much more significant, mainly because of the cardiovascular repercussions of this syndrome. Assuming that MS is increasing worldwide, the need to study the relationship becomes more important when we face two pandemics of COVID-19 and cardiovascular diseases.

    The lack of studies about COVID-19 in patients with MS shows that this subject is still poorly discussed, while studies about each comorbidity isolated and COVID-19 are abundant. In this review, we studied the impact of the four conditions in COVID-19, and we concluded that all of them play an important role as a risk factor and worse prognoses, leading to higher rates of hospitalizations and the need for oxygen and even leading to death. The leading causes for these findings are related to the repercussions that the diseases cause in the host, such as changes in immunity, cytokine levels, receptors, and binders, which can predispose the individual to COVID-19 and agammaavate the condition. When combined with MS, the inflammatory response becomes more severe and leads to unfavorable outcomes, worsening the respiratory condition, and causing other alterations such as cardiac dysfunctions and atherothrombotic events. For these reasons, there is an urgent need for specific protocols to deal with the MS population in COVID-19.


    Acknowledgments



    We want to thank Conacyt for the scholarship for Sergio Alejandro Salazar-Brann.

    Conflict of interest



    Authors declare no conflict of interest.

    [1] Ghorbani-Choghamarani A, Taherinia Z, Heidarnezhad Z, et al. Application of nanofibers based on natural materials as catalyst in organic reactions (2020) . doi: 10.1016/j.jiec.2020.10.028
    [2] Phan DN, Khan MQ, Nguyen NT, et al. (2021) A review on the fabrication of several carbohydrate polymers into nanofibrous structures using electrospinning for removal of metal ions and dyes. Carbohyd Polym 252: 117175. doi: 10.1016/j.carbpol.2020.117175
    [3] Liu M, Deng N, Ju J, et al. (2019) A review: electrospun nanofiber materials for lithium-sulfur batteries. Adv Funct Mater 29: 1905467. doi: 10.1002/adfm.201905467
    [4] Wang H, Niu H, Wang H, et al. (2021) Micro-meso porous structured carbon nanofibers with ultra-high surface area and large supercapacitor electrode capacitance. J Power Sources 482: 228986. doi: 10.1016/j.jpowsour.2020.228986
    [5] Zhang L, Tang Y, Tong L (2020) Micro-/nanofiber optics: Merging photonics and material science on nanoscale for advanced sensing technology. Iscience 23: 100810. doi: 10.1016/j.isci.2019.100810
    [6] Aytac Z, Huang R, Vaze N, et al. (2020) Development of biodegradable and antimicrobial electrospun zein fibers for food packaging. ACS Sustain Chem Eng 8: 15354-15365. doi: 10.1021/acssuschemeng.0c05917
    [7] Feng X, Li J, Zhang X, et al. (2019) Electrospun polymer micro/nanofibers as pharmaceutical repositories for healthcare. J Control Release 302: 19-41. doi: 10.1016/j.jconrel.2019.03.020
    [8] Ngadiman NHA, Yusof NM, Idris A, et al. (2017) Development of highly porous biodegradable γ-Fe2O3/polyvinyl alcohol nanofiber mats using electrospinning process for biomedical application. Mater Sci Eng C 70: 520-534. doi: 10.1016/j.msec.2016.09.002
    [9] Horne J, McLoughlin L, Bridgers B, et al. (2020) Recent developments in nanofiber-based sensors for disease detection, immunosensing, and monitoring. Sensor Actuat Rep 2: 100005. doi: 10.1016/j.snr.2020.100005
    [10] Haghdoost F, Bahrami SH, Barzin J, et al. (2021) Preparation and characterization of electrospun polyethersulfone/polyvinylpyrrolidone-zeolite core–shell composite nanofibers for creatinine adsorption. Sep Purif Technol 257: 117881. doi: 10.1016/j.seppur.2020.117881
    [11] Zhao Y, Qiu Y, Wang H, et al. Preparation of nanofibers with renewable polymers and their application in wound dressing (2016) . doi: 10.1155/2016/4672839
    [12] Parham S, Kharazi AZ, Bakhsheshi-Rad HR, et al. (2020) Electrospun nano-fibers for biomedical and tissue engineering applications: A comprehensive review. Materials 13: 2153. doi: 10.3390/ma13092153
    [13] Haider A, Haider S, Kang IK (2018) A comprehensive review summarizing the effect of electrospinning parameters and potential applications of nanofibers in biomedical and biotechnology. Arab J Chem 11: 1165-1188. doi: 10.1016/j.arabjc.2015.11.015
    [14] Rezaei Soulegani S, Sherafat Z, Rasouli M (2021) Morphology, physical, and mechanical properties of potentially applicable coelectrospun polysulfone/chitosan-polyvinyl alcohol fibrous membranes in water purification. J Appl Polym Sci 138: 49933. doi: 10.1002/app.49933
    [15] Sarode S, Upadhyay P, Khosa MA, et al. (2019) Overview of wastewater treatment methods with special focus on biopolymer chitin-chitosan. Int J Biol Macromol 121: 1086-1100. doi: 10.1016/j.ijbiomac.2018.10.089
    [16] Lee M, Chen BY, Den W (2015) Chitosan as a natural polymer for heterogeneous catalysts support: a short review on its applications. Appl Sci 5: 1272-1283. doi: 10.3390/app5041272
    [17] Ma J, Sahai Y (2013) Chitosan biopolymer for fuel cell applications. Carbohyd Polym 92: 955-975. doi: 10.1016/j.carbpol.2012.10.015
    [18] Nasr A, Gawad SA, Fekry AM (2020) A sensor for monitoring the corrosion behavior of orthopedic drug calcium hydrogen phosphate on a surgical 316L stainless steel alloy as implant. J Bio/Tribo-Corros 6: 36. doi: 10.1007/s40735-020-0334-5
    [19] Dizaji BF, Azerbaijan MH, Sheisi N, et al. (2020) Synthesis of PLGA/chitosan/zeolites and PLGA/chitosan/metal organic frameworks nanofibers for targeted delivery of Paclitaxel toward prostate cancer cells death. Int J Biol Macromol 164: 1461-1474. doi: 10.1016/j.ijbiomac.2020.07.228
    [20] Nitta S, Kaketani S, Iwamoto H (2015) Development of chitosan-nanofiber-based hydrogels exhibiting high mechanical strength and pH-responsive controlled release. Eur Polym J 67: 50-56. doi: 10.1016/j.eurpolymj.2015.03.053
    [21] Mombini S, Mohammadnejad J, Bakhshandeh B, et al. (2019) Chitosan-PVA-CNT nanofibers as electrically conductive scaffolds for cardiovascular tissue engineering. Int J Biol Macromol 140: 278-287. doi: 10.1016/j.ijbiomac.2019.08.046
    [22] Bayat S, Amiri N, Pishavar E, et al. (2019) Bromelain-loaded chitosan nanofibers prepared by electrospinning method for burn wound healing in animal models. Life Sci 229: 57-66. doi: 10.1016/j.lfs.2019.05.028
    [23] Qiu H, Zhu S, Pang L, et al. (2020) ICG-loaded photodynamic chitosan/polyvinyl alcohol composite nanofibers: Anti-resistant bacterial effect and improved healing of infected wounds. Int J Pharmaceut 588: 119797. doi: 10.1016/j.ijpharm.2020.119797
    [24] Kalantari K, Afifi AM, Jahangirian H, et al. (2019) Biomedical applications of chitosan electrospun nanofibers as a green polymer–Review. Carbohyd Polym 207: 588-600. doi: 10.1016/j.carbpol.2018.12.011
    [25] Kurita K (2006) Chitin and chitosan: functional biopolymers from marine crustaceans. Mar Biotechnol 8: 203-226. doi: 10.1007/s10126-005-0097-5
    [26] Kaya M, Akyuz B, Bulut E, et al. (2016) Chitosan nanofiber production from Drosophila by electrospinning. Int J Biol Macromol 92: 49-55. doi: 10.1016/j.ijbiomac.2016.07.021
    [27] Wang W, Meng Q, Li Q, et al. (2020) Chitosan derivatives and their application in biomedicine. Int J Mol Sci 21: 487. doi: 10.3390/ijms21020487
    [28] Rinaudo M (2006) Chitin and chitosan: Properties and applications. Prog Polym Sci 31: 603-632. doi: 10.1016/j.progpolymsci.2006.06.001
    [29] Liu Y, Park M, Shin HK, et al. (2014) Facile preparation and characterization of poly (vinyl alcohol)/chitosan/graphene oxide biocomposite nanofibers. J Ind Eng Chem 20: 4415-4420. doi: 10.1016/j.jiec.2014.02.009
    [30] Xu J, Zhang J, Gao W, et al. (2009) Preparation of chitosan/PLA blend micro/nanofibers by electrospinning. Mater Lett 63: 658-660. doi: 10.1016/j.matlet.2008.12.014
    [31] Zhang H, Wu C, Zhang Y, et al. (2010) Elaboration, characterization and study of a novel affinity membrane made from electrospun hybrid chitosan/nylon-6 nanofibers for papain purification. J Mater Sci 45: 2296-2304. doi: 10.1007/s10853-009-4191-3
    [32] Spasova M, Manolova N, Paneva D, et al. (2004) Preparation of chitosan-containing nanofibres by electrospinning of chitosan/poly (ethylene oxide) blend solutions. E-Polymers 4: 056. doi: 10.1515/epoly.2004.4.1.624
    [33] Desai K, Kit K, Li J, et al. (2008) Morphological and surface properties of electrospun chitosan nanofibers. Biomacromolecules 9: 1000-1006. doi: 10.1021/bm701017z
    [34] Mengistu Lemma S, Bossard F, Rinaudo M (2016) Preparation of pure and stable chitosan nanofibers by electrospinning in the presence of poly (ethylene oxide). Int J Mol Sci 17: 1790. doi: 10.3390/ijms17111790
    [35] Ohkawa K, Cha D, Kim H, et al. (2004) Electrospinning of chitosan. Macromol Rapid Comm 25: 1600-1605. doi: 10.1002/marc.200400253
    [36] Ohkawa K, Minato KI, Kumagai G, et al. (2006) Chitosan nanofiber. Biomacromolecules 7: 3291-3294. doi: 10.1021/bm0604395
    [37] Nirmala R, Il BW, Navamathavan R, et al. (2011) Preparation and characterizations of anisotropic chitosan nanofibers via electrospinning. Macromol Res 19: 345. doi: 10.1007/s13233-011-0402-2
    [38] Nirmala R, Navamathavan R, El-Newehy MH, et al. (2011) Preparation and electrical characterization of polyamide-6/chitosan composite nanofibers via electrospinning. Mater Lett 65: 493-496. doi: 10.1016/j.matlet.2010.10.066
    [39] Geng X, Kwon OH, Jang J (2005) Electrospinning of chitosan dissolved in concentrated acetic acid solution. Biomaterials 26: 5427-5432. doi: 10.1016/j.biomaterials.2005.01.066
    [40] Homayoni H, Ravandi SAH, Valizadeh M (2009) Electrospinning of chitosan nanofibers: Processing optimization. Carbohyd Polym 77: 656-661. doi: 10.1016/j.carbpol.2009.02.008
    [41] Ibrahim HM, Klingner A (2020) A review on electrospun polymeric nanofibers: Production parameters and potential applications. Polym Test 90: 106647. doi: 10.1016/j.polymertesting.2020.106647
    [42] Rinaudo M, Milas M, Le Dung P (1993) Characterization of chitosan. Influence of ionic strength and degree of acetylation on chain expansion. Int J Biol Macromol 15: 281-285. doi: 10.1016/0141-8130(93)90027-J
    [43] Tan SC, Khor E, Tan T K, et al. (1998) The degree of deacetylation of chitosan: advocating the first derivative UV-spectrophotometry method of determination. Talanta 45: 713-719. doi: 10.1016/S0039-9140(97)00288-9
    [44] ASTM D1125-14 Standard Test Methods for Electrical Conductivity and Resistivity of Water, ASTM International, West Conshohocken, PA (2014) .
    [45] Viera DF, Avellaneda CO, Pawlicka A (2008) AC impedance, X-ray diffraction and DSC investigation on gelatin based-electrolyte with LiClO4. Mol Cryst Liq Cryst 485: 843-852. doi: 10.1080/15421400801922304
    [46] Shukur MF, Majid NA, Ithnin R, et al. (2013) Effect of plasticization on the conductivity and dielectric properties of starch–chitosan blend biopolymer electrolytes infused with NH4Br. Phys Scr 2013: 014051. doi: 10.1088/0031-8949/2013/T157/014051
    [47] Bossard F, Rinaudo M (2019) Biomaterials from chitosan processed by electrospinning. Nanoworld J 5: 32-35. doi: 10.17756/nwj.2019-069
    [48] Li Q, Song B, Yang Z, et al. (2006) Electrolytic conductivity behaviors and solution conformations of chitosan in different acid solutions. Carbohyd Polym 63: 272-282. doi: 10.1016/j.carbpol.2005.09.024
    [49] Andrady AL (2008)  Science and Technology of Polymer Nanofibers New Jersey: John Wiley & Sons. doi: 10.1002/9780470229842
  • bioeng-08-01-011-s001.pdf
  • This article has been cited by:

    1. Uri Adrian Prync Flato, Karina Vilariço Ferreira, Piero Biteli, Daniela Ortega Balbo Rodrigues Reina, Fábio Tadeu Rodrigues Reina, Fausto Tucunduva Vernaschi, Gabriela Achete de Souza, Gyovanna Sorrentino dos Santos Campanari, Júlia Novaes Matias, Vinícius Marinho Lima, Tereza Lais Menegucci Zutin, Rogério Leone Buchaim, Daniela Vieira Buchaim, Sandra Maria Barbalho, Rabdomyolysis as a serious complication of COVID-19, 2021, 8, 2375-1495, 165, 10.3934/bioeng.2021015
    2. Arunima Chaudhuri, Suhrita Paul, Tapas Ghosh, Challenges in the Management of COVID-19 Patients with Metabolic Syndrome with Special Emphasis on Gender and Age - A Review, 2021, 8, 23492562, 3401, 10.18410/jebmh/2021/617
    3. Izumi Nagatomo, Kaori Nakanishi, Ryohei Yamamoto, Seiko Ide, Chisaki Ishibashi, Toshiki Moriyama, Keiko Yamauchi-Takihara, Soluble angiotensin-converting enzyme 2 association with lipid metabolism, 2022, 9, 2296-858X, 10.3389/fmed.2022.955928
    4. Simi Kurian, Manu Mathews, V.P. Reshmi, Binoo Divakaran, S. Ajith, Impact of diabetes on the severity of COVID-19 infection in pregnant women - A single-center descriptive study, 2022, 16, 18714021, 102362, 10.1016/j.dsx.2021.102362
    5. Dhruba Das, Hemanta Saikia, Dibyajyoti Bora, Dibyojyoti Bhattacharjee, Jondeep Das, A survival analysis approach for identifying the risk factors in time to recovery of COVID-19 patients using Cox proportional hazard model, 2022, 5, 27726622, 100137, 10.1016/j.dajour.2022.100137
    6. Cong Toai Truong, Kim Hieu Huynh, Van Tu Duong, Huy Hung Nguyen, Le An Pham, Tan Tien Nguyen, Model-free volume and pressure cycled control of automatic bag valve mask ventilator, 2021, 8, 2375-1495, 192, 10.3934/bioeng.2021017
    7. Veena Paul, Abhishek Dutt Tripathi, Aparna Agarwal, Dipendra Kumar Mahato, Kartikeya Srivastava, Kamlesh Kumar Maurya, Herbs-derived phytochemicals – a boon for combating COVID-19, 2023, 2229-4473, 10.1007/s42535-023-00601-9
    8. Lydia Julian, Dyah Ratna Budiani , , Pengaruh Ekstrak Etanolik Daun Kelor (Moringa oleifera, Lam.) Terhadap Ekspresi Reseptor ACE2 Pankreas Tikus Wistar (Rattus Norvegicus) Model Sindrom Metabolik, 2023, 2, 2828-4801, 122, 10.20961/plexus.v2i3.695
  • Reader Comments
  • © 2021 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Metrics

Article views(7288) PDF downloads(599) Cited by(18)

Figures and Tables

Figures(12)  /  Tables(1)

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog